

**DUKE UNIVERSITY MEDICAL CENTER
CURRICULUM VITAE**

for the Permanent Record
and the
Appointment, Promotions and Promotions Committee

Date CV Prepared: May 2, 2025

Name: Stephen John Greene, MD, FACC, FHFA

Preferred familiar name: Steve

Primary academic rank: Associate Professor of Medicine

Primary academic department: Department of Medicine

Other titles: Co-director of the Duke Guideline-Directed Medical Therapy Clinic

Rank and date of first Duke faculty appointment: Assistant Professor of Medicine – July 1, 2020

NC Medical Board license certificate number: North Carolina #2017-01297

Next renewal date: 03/16/2024

Specialty certification and dates: American Board of Internal Medicine, #357223

Internal Medicine	08/18/2015
Cardiovascular Disease	10/09/2018
Advanced Heart Failure and Transplant Cardiology	10/21/2020

Education:

	<u>Institution</u>	<u>Year</u>	<u>Degree</u>
High School	Litchfield High School Litchfield, CT	2004	Diploma
College	Brown University Providence, RI	2008	BA, Biology and Economics Magna Cum Laude
Medical School	Northwestern University Feinberg School of Medicine Chicago, IL	2012	MD

Professional Training and Academic Career:

<u>Institution</u>	<u>Position/Title</u>	<u>Dates</u>
McGaw Medical Center of Northwestern University	Internship, Internal Medicine	2012 – 2013
McGaw Medical Center of Northwestern University	Residency, Internal Medicine	2013 – 2015
Duke University Medical Center	Clinical Cardiology Fellow	2015 – 2017
Duke Clinical Research Institute	Clinical Research Fellow	2017 – 2019
Duke University Medical Center	Advanced Heart Failure Fellow	2019 – 2020
Duke University Medical Center	Assistant Professor of Medicine	2020 – Present
Duke Clinical Research Institute	Faculty Member	2020 – Present

Scholarship

A. Original Research Publications:

1. Gheorghiade M, **Greene SJ**, Filippatos G, Erdmann E, Ferrari R, Levy PD, Maggioni A, Nowack C, Mebazaa A; COMPOSE Investigators and Coordinators. Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. *Eur J Heart Fail*. 2012 Sep;14(9):1056-66. doi: 10.1093/eurjhf/hfs093. Epub 2012 Jun 19. PMID: 22713287.
2. **Greene SJ**, Harinstein ME, Vaduganathan M, Subačius H, Konstam MA, Zannad F, Maggioni AP, Swedberg K, Butler J, Gheorghiade M; EVEREST Trial Investigators. Prognostic value of monocyte count in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). *Am J Cardiol*. 2012 Dec 1;110(11):1657-62. doi: 10.1016/j.amjcard.2012.07.035. Epub 2012 Aug 21. PMID: 22917555.
3. Vaduganathan M, Ambrosy AP, **Greene SJ**, Mentz RJ, Subacius HP, Maggioni AP, Swedberg K, Nodari S, Zannad F, Konstam MA, Butler J, Gheorghiade M; EVEREST trial investigators. Predictive value of low relative lymphocyte count in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. *Circ Heart Fail*. 2012 Nov;5(6):750-8. doi: 10.1161/CIRCHEARTFAILURE.112.970525. Epub 2012 Oct 9. PMID: 23051949.
4. **Greene SJ**, Vaduganathan M, Lupi L, Ambrosy AP, Mentz RJ, Konstam MA, Nodari S, Subacius HP, Fonarow GC, Bonow RO, Gheorghiade M; EVEREST Trial Investigators. Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). *Am J Cardiol*. 2013 Feb 15;111(4):574-81. doi: 10.1016/j.amjcard.2012.10.042. Epub 2012 Dec 1. PMID: 23206923.
5. Lanfear DE, Sabbah HN, Goldsmith SR, **Greene SJ**, Ambrosy AP, Fought AJ, Kwasny MJ, Swedberg K, Yancy CW, Konstam MA, Maggioni AP, Zannad F, Gheorghiade M; EVEREST